Evaxion (NASDAQ: EVAX) schedules May 7 call on Q1 2026 results

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, has scheduled a business update and its first quarter 2026 financial results release for May 7, 2026 before the opening of the Nasdaq CM.

The company’s executive management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Registration is required to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website afterward.

Key Figures

Results release date: May 7, 2026 Conference call time CET: 14:30 CET Conference call time EST: 08:30 EST +1 more

4 metrics

Results release date May 7, 2026 First quarter 2026 financial results and business update

Conference call time CET 14:30 CET Management call on May 7, 2026

Conference call time EST 08:30 EST Management call on May 7, 2026

Employees / experts +40 experts Team covering target discovery to clinical development

Key Terms

TechBio, AI-Immunology™, forward-looking statements, ADSs, +1 more

5 terms

TechBio technical

"Evaxion A/S, a clinical-stage TechBio company developing novel vaccines..."

A techbio company uses advanced engineering, computing and data tools together with biology to design or make new medicines, diagnostics, or bio-based products. For investors, it signals a blend of lab science and software-style innovation: potential for rapid scaling and platform value but also higher research costs, longer development timelines, and technical risk—similar to backing an engineering-driven startup applied to living systems.

AI-Immunology™ technical

"based upon its proprietary, clinically validated and scalable AI-Immunology™ platform"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

forward-looking statements regulatory

"This announcement contains forward-looking statements within the meaning of Section 27A..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

ADSs financial

"our ADSs and ordinary shares, the impact of international economic..."

Annual Report on Form 20-F regulatory

"refer to the risk factors included in our most recent Annual Report on Form 20-F..."

An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On May 4, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: May 4, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM.

Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What did Evaxion A/S (EVAX) announce in this Form 6-K?

Evaxion A/S announced it will provide a business update and report first quarter 2026 financial results on May 7, 2026, before the Nasdaq CM opens. Executive management will present the results and take questions via a conference call and webcast.

When will Evaxion (EVAX) release its Q1 2026 financial results?

Evaxion will release its first quarter 2026 financial results on May 7, 2026, before the opening of the Nasdaq CM. A same-day conference call and webcast at 14:30 CET / 08:30 EST will discuss the update and results in more detail.

How can investors join Evaxion’s Q1 2026 earnings conference call?

Investors can join the conference call by registering in advance via the provided link to receive dial-in telephone numbers and a unique PIN code. The call opens 15 minutes before the event, and a separate webcast link is available for online access.

Will a recording of Evaxion’s May 7, 2026 webcast be available?

Yes. The webcast recording of Evaxion’s May 7, 2026 business update and first quarter 2026 results presentation will be available on the company’s website shortly after the event, allowing investors to review the discussion and Q&A session later.

What does Evaxion A/S focus on as a TechBio company?

Evaxion focuses on developing novel vaccine candidates for cancer and infectious diseases using its proprietary AI-Immunology™ platform. This clinically validated, scalable AI platform supports rapid, efficient and high-quality target discovery, drug design and development performed by a team of over 40 experts.

Who is the primary investor relations contact for Evaxion (EVAX)?

The primary investor relations contact is Mads Kronborg, Vice President, Investor Relations & Communication. The filing lists his phone number as +45 53 54 82 96 and email address as mak@evaxion.ai for investor and media inquiries related to the company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.2 KB